Table 1.
Baseline characteristics.
| Janssen Ad26COV-2 |
Moderna mRNA-1273 |
Pfizer BNT162b2 |
|
|---|---|---|---|
| No. of participants | 20 | 16 | 31 |
| Sex – no. (%) | |||
| Female | 9 (45) | 6 (37) | 16 (52) |
| Male | 11 (55) | 10 (63) | 15 (48) |
| Age, years | |||
| 18–55 years old – no. (%) | 11 (55) | 9 (56) | 25 (81) |
| 56+ years old – no. (%) | 9 (45) | 7 (44) | 6 (19) |
| Mean ± SD | 50.3 ± 15.9 | 48.4 ± 14.7 | 43.2 ± 11.9 |
| Range | 25–77 | 19–66 | 19–62 |
| Race and ethnic group – no. (%)a | |||
| American or Alaska Native | 0 (0) | 0 (0) | 0 (0) |
| Asian | 0 (0) | 0 (0) | 4 (13) |
| Black or African American | 3 (15) | 5 (31) | 10 (32) |
| Multiracial | 3 (15) | 1 (6) | 1 (3) |
| Native Hawaiian or other Pacific Islander | 0 (0) | 0 (0) | 0 (0) |
| White | 14 (70) | 10 (63) | 15 (49) |
| Other race | 0 (0) | 0 (0) | 1 (3) |
| Hispanic or Latino ethnicity | 2 (10) | 2 (13) | 3 (10) |
| Ethnic group not reported or unknown | 1 (5) | 0 (0) | 0 (3) |
| Vaccine doses prior to Novavax boostb | |||
| One dose | 4 | NA | NA |
| Two doses | 16 | 16 | 31 |
| The interval from last prior vaccine dose, weeksc | |||
| Mean ± SD | 32.8 ± 8.9 | 42.2 ± 13.3 | 42.9 ± 13.1 |
| Range | 12.7–54.1 | 14.3–59.0 | 18.7–76.1 |
| Interval between first and second prior vaccine doses, weeksd | |||
| Mean ± SD | 22.5 ± 8.2 | 4.8 ± 1.3 | 3.2 ± 0.5 |
| Range | 15–43 | 4–8.7 | 2.7–5.3 |
| Serology anti N-protein Ab test at baseline | |||
| Negative | 17 (85) | 11 (69) | 20 (65) |
| Positive | 3 (15) | 5 (31) | 11 (35) |
Selected baseline characteristics and retention of participants enrolled who were primed with Ad26COV-2, mRNA-2373, and BNT162b2 and boosted with NVX-CoV2373.
aRace and ethnic group were reported by the participant and were collected as two categories, so percentages in each category do not total 100%.
bNA denotes not applicable because these participants received two vaccine doses as their EUA prime immunization regimen.
cThe interval corresponds to the time since the one-dose Ad26.COV2.S primary vaccine for those who only received one vaccine dose before enrollment in study or the time since the second Ad26.COV2.S (boost) dose or the second mRNA-1273 or BNT162b2 (prime) dose.
dOnly for those participants who received two doses of Ad26.COV2.S (prime and boost) vaccination or two doses of mRNA-1273 or BNT162b2 (prime) vaccination.